---

$1.49

-0.0500 ( -3.25% ) 32.6K

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma, and advancing novel γδ T cell engagers for potential oncology and autoimmune indications.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-05-07	Buy	1148482.00	Kreis Leslie W.
2025-05-07	Buy	1148482.00	Fletcher Aaron G.L.
2024-10-11	Buy	709040.00	Fletcher Aaron G.L.
2024-10-11	Buy	709040.00	Kreis Leslie W.
2024-10-08	Buy	3038743.00	FAIRBAIRN EMILY
2024-06-14	Sale	-33650.00	Brandt Peter C.
2024-06-14	Sale	-33650.00	Graff Jeremy R.
2024-06-14	Sale	-33650.00	Whitfill Travis
2024-06-14	Sale	-33650.00	FAIRBAIRN EMILY
2024-06-14	Sale	-33650.00	Roemer Alan S.